Managing Bone Health in Metastatic Breast Cancer
2 Bekeken
• 07/03/23
0
0
insluiten
administrator
abonnees
Panelists discuss their preference between denosumab (Xgeva) and zoledronic acid (Zometa), which are both currently approved to help reduce the incidence of skeletal-related events (SREs) in patients with metastatic breast cancer (MBC).
To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge
Laat meer zien
Facebook Reacties
SORT BY-
Top Reacties
-
Laatste Reacties